de la Torre-León T, Nava-López JA, Carrillo-Esper R, Hernández-Reguero JL, de la Torre-León MA, Miranda-Contreras A, González-Rangel JL, Pozos-González RI, Lara-Salazar YI, Palma RJA

Language: Spanish
References: 30
Page: 38-44
PDF size: 196.98 Kb.

ABSTRACT

The obstetric hemorrhage (HO) is one of the three principals causes of maternal morbidity and mortality. The multidisciplinary management has contributed to the decrease of mortality but the global rate of secondary deaths in underdeveloped countries has been increased. The initial treatment when we face a patient with HO is to realice an hemotransfusion, sometimes it has done indiscriminately. Every hospital must have a massive transfusion protocol for its treatment, but now a day exists pharmacology strategies that reduces the amount of blood products and also reduces the secondary adverse reactions.
Celaya maternal hospital, has created an strategy that reduce significantly the use of blood products. This strategy has been named obstetric hemorrhage refrigerator; this refrigerator has hemostatics drugs that has been used in the manage of HO (protombine complex concentrate, fibrinogen concentrate, desmopressin acetate, epsilon aminocaproic acid, Tranexamic acid). This refrigerator is a novel an useful management option when you deal with ho patients and it must convert in a basic tool in the operating room, in the unit of intensive care, in the maternal hospitals; in hospitals that doesn’t have blood bank or in hospitals that are so far away and doesn’t count with the correct infrastructure to manage a blood bank or a bleeding station. The physiopathology of the hemorrhage is the backboard for hemostatic reanimation; directed resuscitation strategy, has decreases in a significant way the maternal morbidity and mortality.

REFERENCES

1. World Health Organization. WHO guidelines for the management of postpartum haemorrhage and retained placenta. WHO; 2009. p. 1-62 [Consultado Ago 2015]. Disponible en: http://whqlibdoc.who.int/publications/2009/9789241598514

2. Rath W. Postpartum hemorrhage update on problems of definitions and diagnosis. Acta Obstet Gynecol Scand. 2011;90:421-428.

3. Hernández G, Graciano L, Buensuseso J, Mendoza J, Zamora E. Hemorragia obstétrica posparto: reanimación guiada por metas. Rev Hosp Jua Mex. 2013;80:183-191.

4. Guasch E, Gilsanz F. Hemorragia masiva obstétrica: enfoque terapéutico actual. Med Intensiva. 2016;40:298-310.

5. Collis RE, Collins PW. Haemostatic management of obstetric haemorrhage. Anaesthesia. 2015;70:78-86.

6. Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth. 2012;109:851-863.

7. Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia. 2015;70:166-175.

8. Huissoud C, Carrabin N, Audibert F, Levrat A, Massignon D, Berland M. Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. BJOG. 2009;116:1097-1102.

9. Llau JV, Acosta FJ, Escolar G, Fernández ME, Guasch E, Marco P, et al. Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document). Med Intensiva. 2015;39:483-504.

10. Butwick AJ, Goodnough LT. Transfusion and coagulation management in major obstetric hemorrhage. Curr Opin Anesthesiol. 2015;28:275-284.

11. Briones C, Gutiérrez M, Esquivel L, Díaz de León M, Briones C. Experiencia exitosa con el Código MATER. Rev Asoc Mex Med Crit Ter Int. 2011;25:43-45.

12. Leal S, Muñoz M, Asuero M, Contreras E, García J, Llau J. Documento Sevilla de Consenso sobre alternativas a la transfusión de sangre alogénica. Actualización del Documento Sevilla. Rev Esp Anestesiol Reanim. 2013;60:1-25.

13. Weeks A. The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next? BJOG. 2015;122:202-210.

14. Fernández E, Murillo F, Puppo A, Leal S. Alternativas terapéuticas de la hemorragia masiva. Med Intensiva. 2012;36:496-503.

15. Perez A, Anica E, Zavala B, González G, Carrillo R. Concentrado de fibrinógeno: una opción en el manejo de la hemorragia aguda. Rev Anest Mex. 2016;39:300-304.

16. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists: postpartum hemorrhage. Obstet Gynecol. 2006;108:1039-1047.

17. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 52. May 2009. Prevention and management of postpartum haemorrhage. Available in: www.rcog.org.uk.guidelines

18. Girard T, Mörtl M, Schlembach D. New approaches to obstetric hemorrhage: The postpartum hemorrhage consensus algorithm. Curr Opin Anaesthesiol. 2014;27:267-274.

19. Rossaint R, Bouillon B, Cerny V, Coats T, Duranteau J, Fernández E, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Critical Care. 2016;20:100.

20. Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia. 2015;70:166-175.

21. Carrillo R, Espinoza de los Monteros I, Rosales A, Zepeda A, Alonso D, Sánchez M, et al. Concentrado de complejo protrombínico en el perioperatorio. Rev Mex Anest. 2015;38:35-43.

22. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008 83:137-143.

23. Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anesthesiol. 2008;25:784-789.

24. Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care. 2009;13:1-1.

25. Liumbruno G, Bernnardello F, Lattanzio A, Piccoli P, Rossetti G; Italian Society of Transfusion Medicine and Immunohemathology (SIMTI) Working Party. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus. 2009;7:325-334.

26. Karanth L, Barua A, Kanagasabai S, Nair S. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database of Systematic Reviews 2013;30(4):CD009824.

27. Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, et al. Anti-fi brinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;19(1):CD001886.

28. CRASH -2 Trial. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomized, placebocontrolled trial. Lancet. 2010;376:23-32.

29. Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010;11:40.

30. Muñoz A, Murillo F. El ácido tranexámico disminuye la mortalidad del shock hemorrágico traumático. Punto de vista. Med Intensiva. 2011;35:286-287.